Welcure Drugs (524661)
TurnaroundScore breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹6.99 |
| Market Cap | ₹55.47 Cr |
| P/E Ratio | 1.08 |
| ROCE | 2.53% |
| ROE | 34.77% |
| Dividend Yield | 0% |
| Profit Growth | 1,000% |
| Debt/Equity | — |
| Sales Growth | -100% |
| 52-Week Range | ₹0.23 — ₹6.99 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹0.89 |
Strengths
- Positive net profit of ₹1 Cr in latest quarter despite zero sales suggests some income stream or cost restructuring.
- Reported ROE of 34.77% indicates efficient use of book equity on paper.
- Piotroski F-Score of 6/9 shows moderate financial fundamentals.
- Low absolute market cap of ₹55 Cr offers potential upside if genuine operations restart.
Concerns
- Sales growth -100% and latest quarter sales of ₹0 Cr mean no core operating business.
- P/E of 1.08 and profit growth of 1000% are misleading, likely driven by one-off or non-operating income and a low base.
- P/B of 7.85 against book value ₹0.89 means paying a huge premium to assets; no margin of safety.
- ROCE of 2.53% vs ROE of 34.77% signals poor earnings quality; promoter holding and debt/equity data are unavailable.
AI Analysis
Let me be blunt: this is not a business I can understand from these numbers, and that alone disqualifies it in my book. Welcure Drugs sells at ₹6.99, market cap ₹55 crore, yet latest quarter sales are ₹0 crore. Zero revenue. The company shows ₹1 crore net profit—where did it come from? Not from operations. ROE is 34.77% but ROCE is 2.53%, a huge gap that tells me reported earnings are not generated by productive capital employed. Sales growth is -100%, while profit growth is supposedly 1000%; that is arithmetic from a base of nothing, not a compounding franchise. P/E of 1.08 looks tantalising, but only if the profit is real, recurring, and cash; I have no evidence. Book value is ₹0.89, so paying ₹6.99 means 7.85 times book for a shell with no revenue. The 52-week range of ₹0.23 to ₹6.99 shows the market has already gone mad for it; I don't chase such moves. Piotroski F-score 6/9 is mediocre, and the FairStock Score says insufficient data. Promoter holding is unknown, dividend is nil. This is a penny-stock spectacle, not a business. If there is a genuine turnaround, I need audited financials, a path to real sales, and honest management. Until then, I would rather miss it.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer